KDC-MN-1326 – Kodiac biolabs

Our opinion on this compoundNiche research probe

35/100

Clever prodrug chemistry that outperforms NAC on CNS delivery, but thin human evidence and saturated biology limit its scope

Look, NACET is genuinely clever prodrug chemistry and we mean that sincerely. The core idea is simple: NAC is a polar acid that struggles to cross lipid bilayers and the blood-brain barrier, so you esterify the carboxyl group, turn it into a neutral molecule at physiological pH, and let passive diffusion carry it across. Intracellular esterases cleave the ester bond, NAC is released inside the cell, and glutathione synthesis proceeds from there. The mechanism is well-understood and the pharmacological rationale is real.

The published in vitro data are consistent with the theory. Work out of USC and Italian academic groups during the 2000s reports intracellular GSH elevations of 30 to 50 percent after NACET exposure versus under 10 percent for equimolar NAC. The rodent in vivo picture is similarly supportive: oral NACET produces measurable brain GSH elevation that equimolar oral NAC simply doesnt. That’s a meaningful result, and it is the compound’s best argument for bench utility.

Here’s the thing: the evidence base stops there. No human pharmacokinetic studies of note have been published, and the clinical trial space is essentially empty. Compare that to NAC itself, which has decades of clinical data across acetaminophen overdose, mucolytic applications, and more recently psychiatric indications. NACET has better CNS delivery on paper, but better delivery of a well-understood molecule into a well-studied pathway is not the same as a novel research frontier. The underlying biology, cysteine replenishment driving glutathione synthesis, is one of the most saturated antioxidant circuits in the literature.

The differentiation picture is also muddier than it looks. NAC amide (NACA) is a direct competitor with overlapping lipophilicity and BBB-penetration arguments, and it carries some independent preclinical literature of its own. NACET is not clearly dominant over NACA on any published head-to-head metric; thats a comparison serious investigators should make before committing to a CNS oxidative stress model built around this compound.

What we like: if you’re building a rodent model of oxidative stress-driven neurodegeneration and IP NAC is your current workaround for the bioavailability problem, NACET is worth the evaluation. The esterase-mediated intracellular release is mechanistically clean and well-precedented in prodrug pharmacology. It is a legitimately better tool than plain NAC for any experiment that requires CNS GSH delivery.

What we don’t like: the literature is thin, the human data is essentially nonexistent, and the pathway is familiar territory. NACET makes NAC better. It doesn’t make the research question more interesting, and at this point in time the compound needs a serious investigator willing to generate the first rigorous human PK data before it earns a higher tier.

Novelty: 38
Mechanism promise: 40
In-category differentiation: 40
Evidence quality: 28
Translational signal: 20
Research bench value: 45

Rationale NACET earns credit as a CNS-penetrant glutathione delivery tool with real preclinical support, but zero human clinical data, direct competition from NAC amide, and a fundamentally well-mapped underlying pathway (cysteine-to-GSH) keep all six axes from climbing out of the low-to-mid range.

Lipophilic ester of N-acetylcysteine and glutathione precursor

The ethyl ester of N-acetylcysteine, a lipophilic NAC analog with substantially higher cellular and central nervous system bioavailability than the parent acid.

Abstract

NACET (N-acetyl-L-cysteine ethyl ester; CAS 59587-09-6; molecular formula C7H13NO3S; molecular weight 191.25) is the ethyl ester prodrug of N-acetylcysteine (NAC), developed at the University of Southern California and at Italian academic groups during the 2000s as a lipophilic alternative to NAC with markedly improved cellular and central nervous system bioavailability. The parent NAC is a polar carboxylic acid with low oral bioavailability (approximately 6 to 10 percent), poor blood-brain barrier penetration, and limited intracellular accumulation; NACET is a neutral ester at physiological pH, crosses cell membranes by passive diffusion, and is hydrolyzed intracellularly by ubiquitous esterases to release NAC inside the cell. Published in vitro studies report cellular glutathione (GSH) elevation 30 to 50 percent above baseline after NACET exposure compared to less than 10 percent for equimolar NAC, owing to the difference in cellular delivery. Published rodent in vivo work reports brain GSH elevation after oral NACET that is not detectable after equimolar oral NAC, consistent with the BBB-penetration argument. The pharmacological consequence is that NACET delivers the antioxidant and glutathione-precursor activity of NAC at lower oral doses with central nervous system exposure. Reported applications in research include neuroprotection, oxidative stress modulation, and as a research tool for cysteine delivery in cell culture. Human pharmacokinetic data are limited and no large clinical trials have been published. The compound is not approved by FDA or EMA for any indication. NAC itself is approved as an antidote for acetaminophen overdose and as a mucolytic; the ester form is sold only as a research-grade compound or supplement. Stability is moderate at room temperature; refrigerated storage is preferred for solid material.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1326Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1326

NACET

Abstract

Read the full monograph